PRESS RELEASE
News
-
-
-
-
-
-
-
PRESS RELEASE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking microdosing depression trial with MB22001, showing significant reductions in anxiety, stress, and depression -
PRESS RELEASE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking depression trial using microdoses of psychedelic medicines, showing significant improvements in anxiety, stress, and depression levels -
PRESS RELEASE
Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens. La société se focalise sur le traitement de maladies liées à l'âge, notamment la Dystrophie Musculaire de Duchenne -
PRESS RELEASE
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients
